Nanohybrid Drug Delivery via Nested Shell Encapsulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems using cationic polymers like polyethylenimine face toxicity issues due to uncontrolled electrostatic interactions with biological components and rapid clearance, hindering their clinical translation, especially in cancer treatment where severe side effects are a concern.
Innovation Solution
A nanohybrid drug delivery composition is developed, comprising a multivalent polymeric scaffold with therapeutic agents and targeting agents, encapsulated within a protective shell of liposomes or biodegradable nanoparticles, which controls release and cellular uptake kinetics, leveraging both passive and active targeting mechanisms to enhance therapeutic efficacy and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If cationic polymers like polyethylenimine are used as drug delivery vectors, then cellular internalization is facilitated through spontaneous interaction with biological membranes, but toxicity increases due to uncontrolled electrostatic interactions with blood components and rapid clearance by the reticuloendothelial system
Solution Approach 1:
The patent encapsulates the cationic polymeric scaffold within a protective nanoparticle shell, creating a nested structure where the inner core contains the active polymer while the outer shell provides biocompatibility. This nesting allows the cationic polymer to maintain its cellular internalization capability while the shell protects it from uncontrolled electrostatic interactions with blood components and reduces reticuloendothelial system clearance.
Solution Approach 2:
The nanoparticle shell acts as an intermediary between the cationic polymer and the biological environment. It mediates the interaction by providing a biocompatible interface that reduces direct contact between the toxic cationic polymer and blood components, while still allowing controlled delivery to target cells.
2Reliability
If the nanoscale delivery system size is reduced to 50-200 nm to take advantage of the EPR effect for passive targeting, then tumor site accumulation is enhanced, but the payload capacity and stability of the delivery system are reduced
Solution Approach 1:
The patent creates a composite nanoparticle structure combining a polymeric scaffold with a protective shell material. This composite approach allows the small nanoparticle to maintain structural integrity and stability while providing sufficient payload capacity through the high-density polymeric core, overcoming the limitations of small size for drug loading.
3Reliability
If ligands for receptor-mediated endocytosis are added to achieve active targeting, then specificity to target cells is improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent designs the nanoparticle shell to serve multiple functions simultaneously: it provides biocompatibility, enables passive targeting through EPR effect, and can be functionalized with ligands for active targeting. The polymeric scaffold itself can also provide targeting capability through its cationic nature, reducing the need for additional specialized ligands and simplifying the overall system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanohybrid composition achieves sustained release profiles, reduced cytotoxicity, and enhanced targeting efficacy by controlling the kinetics of drug release and cellular uptake, thereby improving the therapeutic index of anti-cancer agents and minimizing side effects.
Implementation Method 1
Passive targeting utilizes the enhanced permeability and retention (EPR) effect that is defined by leaky vasculature and poor lymphatic drainage around tumors, resulting in the accumulation of the nanoscale delivery system at the tumor site.
Implementation Method 2
Another characteristic of PEI and other polycations, such as poly(lysine) and poly(amidoamine) (PAMAM) dendrimers, is that they spontaneously interact with biological membranes. This facilitates their cellular internalization without the need for ligands for receptor-mediated endocytosis or other internalization routes.
Data Source
AI summary
The present invention features nanohybrid drug delivery composition which combines both passive and active targeting for the prevention and treatment of disease. The composition is shell-encapsulated multivalent polymeric scaffold with a therapeutic agent and targeting agent attached thereto.